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ABSTRACT 
A Controlled release dosage forms have been extensively used to improve therapy with several 
important drugs. However, the development processes are faced with several physiological difficulties 
such as the inability to restrain and localize the system within the desired region of the gastrointestinal 
tract and the highly variable nature of the gastric emptying process. This variability may lead to 
unpredictable bioavailability and times to achieve peak plasma levels. The present review addresses 
briefly about the classification, formulation consideration for GRDDS, factors controlling gastric 
retention, merits, demerits and applications of gastroretentive drug delivery systems. 
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Introduction 
A drug that is released from a dosage form in a 
controlled manner in the stomach will empty 
together with fluids and will have the whole 
surface area of the small intestine available for 
absorption[1]. Oral drug delivery has been 
known for decades as the most widely used 
route of administration among all the routes 
that have been explored for the systemic 
delivery. Oral route is the most convenient and 
extensively used route of drug administration. 
All controlled release systems have limited 
applications if the systems cannot remain in 
the vicinity of the absorption site. The 
controlled release drug delivery system 
possessing the ability of being retained in the 
stomach is called gastro retentive drug delivery 
system. They can help in optimizing the oral 
controlled delivery of drugs having 
“absorption window” continually releasing the 
drug prior to absorption window for prolonged 
period of time, thus ensuring optimal 
bioavailability. Gastric emptying occurs during 
fasting as well as fed states. The pattern of 
motility is, however, distinct in the two states. 
Gastric emptying studies revealed that orally 
administered controlled release dosage forms 
are subjected to basically two complications: 
that of short gastric residence time and 
unpredictable gastric emptying rate[2]. 
Table 1: Comparison between conventional and gastro retentive drug delivery system [3] 
Parameters  
 
Gastroretentive Drug 
Delivery System  
 
Conventional Drug Delivery 
System  
 
Risk of toxicity  
 
Lower Higher 
Patient compliance  
 
High compliance level Less compliance level 
Dose dumping  
 
High risk  No risk  
 
Drugs  
 
Beneficial for drugs: That 
have rapid GI absorption  
Degrade in colon 
 
Not beneficial for drugs:  
That have low GI absorption  
Degrade in colon 
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Need for GRDDS 
• Conventional oral delivery is widely used 
in pharmaceutical field to treat diseases. 
However, conventional delivery had 
many drawbacks and major draw-back is 
non-site specificity. 
• Some drugs are absorbed at specific site 
only. They require release at specific site 
or a release such that maximum amount 
of drug reaches to the specific site. 
• Pharmaceutical field is now focusing 
towards such drugs which require site 
specificity. 
• Gastro-retentive delivery is one of the 
site specific delivery for the delivery of 
drugs either at stomach or at intestine. It 
is obtained by retaining dosage form into 
stomach and drug is being released at 
controlled manner to specific site either 
in stomach, duodenum and intestine [4]. 
 
Basic Gastrointestinal Tract Physiology [5-
7] 
 
Anatomically the stomach is divided into 3 
regions: fundus, body, and antrum (pylorus). 
The proximal part made of fundus and body 
acts as a reservoir for undigested material, 
whereas the antrum is the main site for mixing 
motions and act as a pump for gastric 
emptying by propelling actions.13 Gastric 
emptying occurs during fasting as well as fed 
states. The pattern of motility is however 
distinct in the 2 states. During the fasting state 
an interdigestive series of electrical events take 
place, which cycle both through stomach and 
intestine every 2 to 3 hours.14 This is called 
the interdigestive myloelectric cycle or 
migrating myloelectric cycle (MMC), which is 
further divided into following 4 phases as 
described by Wilson and Washington. 
 
Fig.1: Anatomy of the gastrointestinal tract 
 
1. Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions. 
2.  Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent action potential and 
contractions. As the phase progresses the intensity and frequency also increases gradually. 
3.  Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and regular contractions 
for short period. It is due to this wave that all the undigested material is swept out of the 
stomach down to the small intestine. It is also known as the housekeeper wave. 
4. Phase IV lasts for 0 to 5 minutes and occurs between phases III and I of 2 consecutive cycles. 
 
 
 
Fig.2 Schematic representation of inter digestive motility 
 
After the ingestion of a mixed meal, the pattern 
of contractions changes from fasted to that of 
fed state. This is also known as digestive 
motility pattern and comprises continuous 
contractions as in phase II of fasted state. 
These contractions result in reducing the size 
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of food particles (to less than 1 mm), which are 
propelled toward the pylorus in a suspension 
form. During the fed state onset of MMC is 
delayed resulting in slowdown of gastric 
emptying rate.16 Scintigraphic studies 
determining gastric emptying rates revealed 
that orally administered controlled release 
dosage forms are subjected to basically 2 
complications, that of short gastric residence 
time and unpredictable gastric emptying rate 3. 
 
Factors Controlling Gastric Retention Time 
 
Retention of Dosage Forms 
The stomach anatomy and physiology contain 
parameters to be considered in the 
development of gastroretentive dosage forms. 
To pass through the pyloric valve in to the 
small intestine the particle size should be in the 
range of 1 to 2 mm .  
Density of dosage forms 
The density of a dosage form also affects the 
gastric emptying rate and determines the 
location of the system in the stomach. Dosage 
forms having a density lower than the gastric 
contents can float tothe surface, while high 
density systems sink to bottom of the stomach 
[16]. Both positions may isolate the dosage 
system from the pylorus. A density of < 1.0 
gm/ cm3 is required to exhibit floating 
property. 
Shape and size of the dosage form 
Shape and size of the dosage forms are 
important in designing indigestible single unit 
solid dosage forms. The mean gastric residence 
times of nonfloating dosage forms are highly 
variable and greatly dependent on their size, 
which may be large,medium and small units. 
In most cases, the larger the dosage form the 
greater will be the gastric retention time (GRT) 
due to the larger size of the dosage form would 
not allow this to quickly pass through the 
pyloric antrum into the intestine . Dosage 
forms having a diameter of more than 7.5 mm 
show a better gastric residence time compared 
with one having 9.9 mm . Ring-shaped and 
tetrahedron-shaped devices have a better 
gastric residence time as compared with other 
shapes . 
 Food intake and its nature 
Food intake, viscosity and volume of food, 
caloric value and frequency of feeding have a 
profound effect on the gastric retention of 
dosage forms. The presence or absence of food 
in the gastrointestinal tract (GIT) influences 
the gastric retention time (GRT) of the dosage 
form. Usually the presence of food in the 
gastrointestinal tract (GIT) improves the 
gastric retention time (GRT) of the dosage 
form and thus, the drugs absorption increases 
by allowing its stay at the absorption site for a 
longer period. Again, increase in acidity and 
caloric value shows down gastric emptying 
time (GET), which can improve the gastric 
retention of dosage forms. 
 
Effect of gender, posture and age 
Generally females have slower gastric 
emptying rates than male. The effect of posture 
does not have any significant difference in the 
mean gastric retention time (GRT) for 
individuals in upright, ambulatory and supine 
state. In case of elderly persons, gastric 
emptying is slowed down[6] . 
 
Advantages of Gastroretentive Drug 
Delivery Systems  
 
1) The bioavailability of therapeutic agents 
can be significantly enhanced especially 
for those which get metabolized in the 
upper GIT by this gastroretentive drug 
delivery approach in comparison to the 
administration of nongastroretentive drug 
delivery. There are several different 
factors related to absorption and transit of 
the drug in the gastrointestinal tract (GIT) 
that act concomitantly to influence the 
magnitude of drug absorption.  
2)  For drugs with relatively short half life, 
sustained release may result in a flip- flop 
pharmacokinetics and also enable reduced 
frequency of dosing with improved patient 
compliance. 
3) They also have an advantage over their 
conventional system as it can be used to 
overcome the adversities of the gastric 
retention time (GRT) as well as the gastric 
emptying time (GET). As these systems 
are expected to remain buoyant on the 
gastric fluid without affecting the intrinsic 
rate of employing because their bulk 
density is lower than that of the gastric 
fluids. 
4) Gastroretentive drug delivery can produce 
prolong and sustain release of    drugs 
from dosage forms which avail local 
therapy in the stomach and small intestine. 
Hence they are useful in the treatment of 
disorders related to stomach and small 
intestine.  
5) The controlled, slow delivery of drug form 
gastroretentive dosage form provides 
sufficient local action at the diseased site, 
thus minimizing or eliminating systemic 
exposure of drugs. This site-specific drug 
delivery reduces undesirable effects of 
side effects. 
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6) Gastroretentive dosage forms minimize 
the fluctuation of drug concentrations and 
effects. Therefore, concentration 
dependent adverse effects that are 
associated with peak concentrations can be 
presented. This feature is of special 
importance for drug with a narrow 
therapeutic index[7] . 
7) Disadvantages of Gastro-Retentive 
Drug Delivery Systems  
 
1. Unsuitable for drugs with limited 
acidsolubility. E.g. Phenytoin.  
2. Unsuitable for drugs those are unstable 
inacidic environment. E.g.Erythromycin. 
3.  Drugs that irritates or causes gastric 
lesions on slow release. E.g. Aspirin 
&NSAID’s.  
4. Drugs that absorb selectively in colon 
E.g. Corticosteroid. 
 
 
Approaches for GRDDS [8-10] 
 
Fig.3 Different Gastroretentive approaches 
 
Effervescent system 
Gas generating system  
Volatile liquid containing system 
Effervescent systems include use of gas 
generating agents, carbonates (ex.Sodium 
bicarbonate) and other organic acid (e.g. citric 
acid and tartaric acid) present in the 
formulation to produce carbon dioxide (CO2) 
gas, thus reducing the density of the system 
and making it float on the gastric fluid. An 
alternative is the incorporation of matrix 
containing portion of liquid, which produce 
gas that evaporates at body temperature. 
 
Effervescent (gas generating) systems  
Floatability can be achieved by generation of 
gas bubbles. These buoyant systems utilize 
matrices prepared with swellable polymers 
such as polysaccharides (e.g. chitosan), 
effervescent components (e.g. sodium 
bicarbonate, citric acid or tartaric acid) . The 
optimal stoicheometric ratio of citric acid and 
sodium bicarbonate for gas generation is 
reported to be 0.76: 1  . In this system carbon 
dioxide is released and causes the formulation 
to float in the stomach .Other approaches and 
materials that have been reported are a mixture 
of sodium alginate and sodium bicarbonate, 
multiple unit floating dosage forms that 
generate gas (carbon dioxide) when ingested, 
floating mini capsules with a core of sodium 
bicarbonate, lactose and polyvinyl pyrrolidone 
(PVP) coated with hydroxypropyl 
methylcellulose (HPMC), and floating system 
based on ion exchange resin technology etc .  
 
 
 
Fig.4: Drug release from effervescent (Gas generating) systems 
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Bilayer or multilayer system has also been 
designed. Drugs and excipients can be 
formulated independently and the gas 
generating material can be incorporated in to 
any of the layers. Further modifications 
involve coating of the matrix with a polymer 
which is permeable to water, but not to carbon 
dioxide. The main difficulty of these 
formulations is finding a good compromise 
between elasticity, plasticity and permeability 
of the polymers 
 
Non- effervescent system 
 
o Colloidal gel barrier system 
o Micro porous compartment system 
o Floating microspheres 
o Alginate floating beads 
o Raft forming systems 
 
The Non-effervescent FDDS is based on 
mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The 
most commonly used excepient in non 
effervescent FDDS are gel forming or highly 
swellable cellulose type hydrocolloids, 
hydrophilic gums, polysaccharides and matrix 
forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as 
well as bioadhesive polymers such as Chitosan 
and carbopol. 
 
Microballoons/ Hollow microspheres 
Microballoons / hollow microspheres loaded 
with drugs in their other polymer shelf were 
prepared by simple solvent evaporation or 
solvent diffusion / evaporation methods  to 
prolong the gastric retention time (GRT) of the 
dosage form. Commonly used polymers to 
develop these systems are polycarbonate, 
cellulose acetate, calcium alginate, Eudragit S, 
agar and low methoxylated pectin etc. 
Buoyancy and drug release from dosage form 
are dependent on quantity of polymers, the 
plasticizer polymer ratio and the solvent used 
for formulation. The microballoons floated 
continuously over the surface of an acidic 
dissolution media containing surfactant for >12 
hours . At present hollow microspheres are 
considered to be one of the most promising 
buoyant systems because they combine the 
advantages of multiple-unit system and good 
floating. 
 
Alginate beads 
 Recently developed a multiple-unit floating 
system based on cross-linked beads. They were 
made by using Ca2+ and low methoxylated 
pectin (anionic polysaccharide) or Ca2+ low 
methoxylated pectin and sodium alginate. In 
this approach, generally sodium alginate 
solution is dropped into aqueous solution of 
calcium chloride and causes the precipitation 
of calcium alginate. These beads are then 
separated and dried by air convection and 
freeze drying, leading to the formulation of a 
porous system, which can maintain a floating 
force for over 12 hrs. These beads improve 
gastric retention time (GRT) more than 5.5 hrs. 
 
Microporous compartment system 
This approach is based on the principle of the 
encapsulation of a drug reservoir inside a 
microporous compartment with pores along its 
top and bottom walls . The peripheral walls of 
the device were completely sealed to present 
any direct contact of the gastric surface with 
the undissolved drug. In the stomach the 
floatation chamber containing entrapped air 
causes the delivery system to float in the 
gastric fluid . Gastric fluid enters through the 
aperture, dissolves the drug and causes the 
dissolved drug for continuous transport across 
the intestine for drug absorption. 
 
 
Applications of GRDDS [11] 
Sustained drug delivery  
Floating system remains in the stomach for 
longer period and release the drug over a 
prolong period of time. This system has bulk 
density less than 1 so it may float on the 
gastric content. 
 
Site specific drug  
This system is particularly advantageous for 
the drugs which are absorbed from the stomach 
or proximal part of the small intestine. 
 
Absorption enhancement  
Drugs having a poor bioavailability are 
potential candidate for formulating as a 
floating system to enhance its absorption.  
 
Maintenance of constant blood flow 
This system provides an easy way for 
maintaining constant blood flow with 
relatively ease of administration. 
 
 
 
 
International Journal of Health and Biological Sciences                Vol. 2, No. 2; 2019:1-8 
e-ISSN: 2590-3357; p-ISSN:2590-3365 
DOI: https://doi.org/10.30750/ IJHBS.2.2.1 
6 
 
Table 2: Drug used in the gastro-retentive formulation [12,13] 
Types Examples 
Floating 
Granules 
Diclofenac sodium, Indomethacin and Prednisolone, Ranitidine 
Hydrochloride-Gelucire. 
 Aspirin, Griseofulvin, ciprofloxacin hydrochloride, P-nitro aniline, 
Indomethasone, 
Ibuprofen, Ketoprofen, Piroxicam, Verapamil, orlistat, 
Cholestyramine, Theophylline, 
Nifedipine, Nicardipine, captorlil, cimetidine, Dipyridamol , Tranilast 
and Terfinadine 
Films Cinnarizine, Albendazole 
Table 3: Other Excepient (Excepient used in GRDDS) [14] 
                    Types                  Examples 
Polymers hydroc Pectin, Chitosan, Agar, Casein, Bentonite, 
Veegum, Hydroxy Propyl MethylCellulose 
(HPMC) (K4M, K100M and K15M), Gellan 
gum(Gelrite, Sodium Carboxy Methyl Cellulose 
(CMC), Methyl Cellulose (MC), Hydroxy Propyl 
Cellulose (HPC). 
Inert fatty 
Material 
Bees wax, Fatty acids, Long chain fatty alcohols, 
Gelucires® 39/01 and 43/01. 
Effervescent 
Agents 
Sodium bicarbonate, Citric acid, Tartaric acid, 
Di-SGC (Di-Sodium Glycine Carbonate), 
CG (Citroglycine). 
Release rate 
Accelerators 
Lactose, Mannitol 
Increasing 
agents- 
Ethyl cellulose. 
Low density 
Material 
Polypropylene foam powder (Accurel MP 
1000®). 
 
Evaluation of floating drug delivery system 
 Evaluation of powder blend fora) 
 Angle of Repose 
 Bulk Density 
 Percentage porosity 
 
Evaluation of tablets fora) 
 Buoyancy capabilities 
 In vitro floating and dissolution behavior 
 Weight variation 
 Hardness & friability 
 Particle size analysis, surface 
characterization (for floating 
microspheres and beads) 
 X‐Ray/Gamma Scintigraphy 
Pre compression parameters  
Bulk density 
A quantity of drug powder was weighed 
initially and was introduced in to 10 ml 
measuring cylinder. The bulk volume was 
determined and the apparent bulk density in 
g/ml was calculated using the formula Bulk 
density=weight of powder/bulk volume[15]. 
Tapped density 
A quantity of drug powder blend from each 
batch, previously shaken to break any 
agglomerates formed, was introduced in to 10 
ml measuring cylinder. After that the initial 
volume was noted and the cylinder was 
allowed to tap under its own weight on to a 
hard surface from the height of 2.5cm at 
second intervals. Tapping was continued until 
no further change in volume was noted[16]. 
Tapped density=weight of powder/tapped 
volume 
Angle of repose 
Angle of repose is defined as “the maximum 
angle possible between the surface of the pile 
of powder and the horizontal plane.” Lower the 
angle of repose, better the flow properties. The 
angle of repose may be calculated by 
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measuring the height (h) of the pile and the 
radius of the base(r) with ruler[17].  
Tan _ = h/r 
Percentage porosity  
 
Whether the powder is porous or nonporous, 
the total porosity expression for the calculation 
remains the same. Porosity provides 
information about hardness, disintegration, 
total porosity etc[18]. 
% porosity, € = void volume × 100 / Bulk 
volume 
% porosity, € = (bulk volume – true volume) 
× 100 / True density 
 
Particle size analysis, surface 
characterization (for floating microspheres 
and beads)  
  
the particle size andthe size distribution of 
beads or microspheres are determined in the 
dry state using the optical microscopy method. 
The external and cross‐sectional morphology 
(surface characterization) is done by scanning 
electron microscope (SEM)[19]. 
 
Drug release study 
The drug release study for the Floating tablets 
were carried out in USP XXIII type-II 
dissolution test apparatus (Paddle type) using 
900 ml of 0.1 N HCl as dissolution medium at 
50 rpm and temperature 37±0.5°C. At 
predetermined time intervals, 5 ml of the 
samples were withdrawn by means of a syringe 
fitted with a pre-filter, the volume withdrawn 
at each interval was replaced with same 
quantity of fresh dissolution medium. The 
resultant samples were analyzed for the 
presence of the drug release by measuring the 
absorbance at λmax of API (nm) using UV 
Visible spectrophotometer after suitable 
dilutions. The determinations were performed 
in triplicate (n=3)[20]. 
Table 4: List of Drugs Formulated as Single and Multiple Unit Forms of Floating Drug Delivery 
Systems [21,22] 
                   Dosage Forms                   Drugs  
Floating tablets and Pills  
 
Cinnarizine, p-Aminobenzoic acid, Prednisolone and Piretanide  
Floating Films  
 
Acetaminophen, Isosorbide mononitrate, Ampicillin, Atenolol, 
Theophylline, p-aminobenzoic acid, Aspirin, Verapamil 
hydrochloride, Sotalol  
Floating microspheres  
 
Aspirin, p-nitroaniline, Griseofulvin, Ketoprofen, Ibuprofen, 
Verapamil and Terfinadine  
Floating Capsules  
 
Diazepam, Furosemide, Misoprostol, L-Dopa and Benserazide, 
Pepstatin, Verapamil HCl and Nicardipine  
Floating powders  
 
Riboflavin, Phosphate, Sotalol and Theophylline  
Floating granules  
 
Diclofenac sodium, Indomethacin, Prednisolone, Cinnarizine, 
Diltiazem, Fluorouracil and Isosorbide mononitrate  
 
Conclusion 
Gastro retentive drug delivery technologies 
have been extensively explored in recent years. 
GRDDS has the potential to enable many 
drugs to provide less frequent dosing and 
remains undoubtedly beneficial for the drugs 
having NAW in the stomach and/or upper part 
of the intestine. All these gastroretentive drug 
delivery systems (high density, floating, 
expandable or unfoldable or swelling, 
superporous, Bioadhesive, magnetic systems 
etc.) are interesting and present their own 
advantages and disadvantages. Now, a lot of 
work is running to develop different types of 
gastro retentive delivery systems of various 
drugs. In the future, it is expected that they will 
become of increasing importance, ultimately 
leading to improved efficiencies of various 
types of pharmacotherapy. 
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